Gyre Therapeutics reported third quarter 2026 financial results, beating analyst estimates for both revenue and EPS while affirming its full-year 2026 revenue guidance. The company’s performance was bolstered by growth in its lead fibrosis product, Etuary, which helped offset the expiration of the Astellas collaboration agreement. Management emphasized the successful integration of Cullgen operations and the completion of NMPA onsite inspections for F351, positioning the company for a potential commercial launch in the first half of 2027.
Key Highlights
- Earnings Beat: Revenue of $32.9 million exceeded consensus estimates of $32.4 million, while basic GAAP EPS loss of $0.04 was significantly narrower than the anticipated $0.14 loss.
- Pipeline Milestone: The China NMPA completed onsite inspections of manufacturing and clinical sites for F351; a regulatory decision is expected by Q1 2027 with a projected 1H 2027 launch.
- Segment Performance: Flagship product Etuary generated $31.4 million in sales, representing 13.4% year-over-year growth from $27.7 million in the prior year period.
- Financial Position: The company ended the quarter with $98.8 million in total cash and investments, compared to $116.1 million at year-end 2025, reflecting clinical advancement and acquisition costs.